
This article was downloaded by: [University of Connecticut] On: 13 October 2014, At: 22:32 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

## Synthesis of a New Analog of Thymidine for In Vivo Non-radioactive Labeling of DNA

Ch. Rodríguez-Tanty<sup>a</sup>, R. Pérez<sup>a</sup>, J. Miranda<sup>b</sup>, H. Vélez-Castro<sup>a</sup>, A. Rosado<sup>a</sup>, A. Macias<sup>a</sup>, L. Galán<sup>a</sup>, D. Higginson-clarke<sup>b</sup> & A. M. Riverón<sup>b</sup>

<sup>a</sup> Organic Chemistry Department, National Center for Scientific Research, PO Box 6880, Havana, Cuba

<sup>b</sup> Molecular Biology Department, National Center for Scientific Research, PO Box 6880, Havana, Cuba Published online: 04 Oct 2006.

To cite this article: Ch. Rodríguez-Tanty , R. Pérez , J. Miranda , H. Vélez-Castro , A. Rosado , A. Macias , L. Galán , D. Higginson-clarke & A. M. Riverón (1999) Synthesis of a New Analog of Thymidine for In Vivo Non-radioactive Labeling of DNA, Nucleosides and Nucleotides, 18:4-5, 1113-1117, DOI: 10.1080/15257779908041663

To link to this article: <u>http://dx.doi.org/10.1080/15257779908041663</u>

### PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>

## SYNTHESIS OF A NEW ANALOG OF THYMIDINE FOR *IN VIVO* NON-RADIOACTIVE LABELING OF DNA

Ch. Rodríguez-Tanty<sup>1\*</sup>, R. Pérez<sup>1</sup>, J. Miranda<sup>2</sup>, H. Vélez-Castro<sup>1</sup>, A. Rosado<sup>1</sup>, A. Macías<sup>1</sup>, L. Galán, D. Higginson-Clarke<sup>2</sup>, A.M. Riverón<sup>2</sup>.

<sup>1</sup>Organic Chemistry Department, <sup>2</sup>Molecular Biology Department, National Center for Scientific Research, PO Box 6880, Havana, Cuba.

**ABSTRACT:** The introduction of 6-(*p*-bromobenzoylamino)caproyl radical in the methyl group of 2'-O-deoxythymidine is described. In vivo incorporation of this nucleoside to DNA was determined using a monoclonal antibody that recognized the radical.


Inmunochemical labels have been successfully introduced at the base position of nucleosides <sup>1-8</sup>; however, they have never been introduced in the methyl group of thymidine. Here, we describe a procedure for synthesizing  $5-\{-N-[caproy]-6-(p-bromobenzamine)]$ aminomethyl $\}-2'-O$ -deoxyuridine (7), which contains 6-(p-bromobenzamine)caproyl (BLC)<sup>7</sup> in the methyl group of thymidine. Results of *in vivo* DNA labeling using this new nucleoside are also discussed.

### **RESULTS AND DISCUSSION**

**Chemical Discussion**: Compound  $\underline{7}$  was synthesized in six steps (scheme 1) and three of them (bromination, azidation and deacylation) were done in one pot. The intermediate  $\underline{3}$  was prepared from  $\underline{2}$  (scheme 1) as reported<sup>9</sup>, but modifying the purification step (see Experimental). Further, the azide anion displaced the bromine atom of  $\underline{3}$ , and finally, the acetyl groups were removed from  $\underline{4}$ . The overall yield of product  $\underline{5}$ , starting from  $\underline{2}$  was 36 %. Azide group of  $\underline{5}$  was reduced according to Knouzi<sup>10</sup>. The structure of compounds <u>5</u>and <u>6</u> were determined using IR, <sup>1</sup>H-, <sup>13</sup>C-NMR and FAB-MS spectra. Finally, to obtain compound <u>7</u>, the <u>6</u> was treated with 6-(*p*-bromobenzoylamino)caproic acid *N*-hydroxysuccinimide <sup>7.8</sup>. IR; NMR; FAB-MS and quantitative elemental analysis were used to characterize <u>7</u>.

**Biological Discussion**. *In vivo* incorporation of modified thymidine to DNA can be done efficiently using Thy mutants (cells lacking the ability of endogenous thymidine synthesis) and adding to the growth medium the nucleoside analog. A direct competitive ELISA determined *in vivo* incorporation of <u>7</u> to nuclear *Escherichia coli* (Thy<sup>-</sup>) DNA. Previous to the ELISA, labeled DNA molecules were hydrolyzed by using DNAase, and further, free modified nucleotides and the immobilized hapten compete for capturing the MAb. To estimate the nucleotide concentrations, the recorded absorbances were replaced in a previously obtained calibration curve. The calibration curve, Abs = b2 + (b1-b2) / [1 + (nucl.conc/b3)<sup>b4</sup>]<sup>-11</sup> (Eq. 1), had b1 = 9.05571 x10<sup>-2</sup>, b2 = 2.32773, b3 = 9.48242 x10<sup>-8</sup> and b4 = 1.86328. In three independent labeling experiments, 1 µg of DNA was isolated, and their absorbances in the ELISAs were 0.262, 0.262 and 0.292, resulting in 2.49 x10<sup>-8</sup> M, 2.49 x10<sup>-8</sup> M and 2.74 x10<sup>-8</sup> M nucleotide concentration, respectively. These concentrations indicate that nearly 0.05 % of thymidine was replaced by the analog during DNA synthesis.

EXPERIMENTAL. Chemical Synthesis. All solvent were dried and stored as described <sup>7.8</sup>. Spectral measures were recorded as reported <sup>7,8</sup>, 5-Bromo 3', 5'-di-O-acetyl-2'-O-deoxythymidine (3); was obtaining from 3',5'-di-O-acetyl-2'-O-deoxythymidine<sup>12</sup>, as reported<sup>9</sup>. The product was isolated by removing the solvent in vacuum, and it was used without further purification in the next step. 5-Azido-2'-O-deoxythymidine (5): Sodium azide (1,19 g, 0,018 mol) was added to a solution of <u>3</u> (0,0092 mol) in dry acetonitrile (120 mL). When the reaction was over (checked by TLC), the solvent was removed, and the syrup (4) was dissolved in a solution of NH<sub>3</sub>/CH<sub>3</sub>OH (8 N) for removing the acetyl groups. The product was purified by column chromatography (chloroform:methanol, from 90:1 to 90:3). Yield: 36%, m.p.: 139-41 °C (lit<sup>13</sup> m.p.: 130-32 °C). IR: 3400s, 3050s, 2950s, 2150s (vN<sub>3</sub>), 1680s, 1460s, 1420s, 1280s, 1200m, 1100s, 1060s, 1000m, 960w, 880m, 760m, 660w. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 11,55 (1H, s. NH): 7,6 (1H, m, 6-CH); 6,16 (1H, t, 1'-CH); 5,8 (1H, s, 3'-OH); 5,05 (1H, s, 5'-OH); 4,25 (1H, s, 3'-CH); 4,05 (2H, s, CH<sub>2</sub>N<sub>3</sub>); 3.8 (1H, s, 4'-CH); 3.55 (2H, s, 5'-CH<sub>2</sub>); 2.1 (2H, s, 2'-CH<sub>2</sub>). <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>): 162,76 (c, 4-CO); 150,08 (c, 2-CO); 139,77 (t, 6-CH); 108,14 (c, 5-C'); 87,36 (t, 4'-CH); 84,15 (t, 1'-CH); 70,12 (t, 3'-CH); 61,11 (s, 5'-CH<sub>2</sub>); 46,78 (s, CH<sub>2</sub>N<sub>3</sub>); 39,53 (s, 2'-CH<sub>2</sub>). FAB-MS (m/z) = 284 (M+H)<sup>+</sup>. 5-Amino-2'-O-deoxythymidine (6): The synthesis was carried out according to the procedure for reducing azide group to amine group<sup>10</sup>. Yield: 74%, m.p.: 172-74 °C. IR: 3400s, 3050m, 2890m, 1660s. 1520s,



1480s, 1400m, 1360m, 1320m, 1280m, 1200w, 1100m, 1060m, 800w, 730w, 700w. <sup>1</sup>H-NMR (DMSOd<sub>6</sub>): 7,75(1H, s, NH); 7,6 (1H, m, 6-CH); 6,2 (1H, t, 1'-CH); 5,5-4,5 (4H, m, 5'-OH + 3'-OH + NH<sub>2</sub>): 4,25 (1H, s. 3'-CH); 3,68 (1H, a, 4'-CH); 3,6-3,5 (4H, 5'-CH<sub>2</sub> + CH<sub>2</sub>NH); 2.14 (2H, s, 2'-CH<sub>2</sub>). <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>): 163.19 (c, 4-CO); 150,31 (c, 2-CO); 135,89 (t, 6-CH); 115,51 (c, 5-C); 87.23 (t, 4-CH); 83,79 (t, 1'-CH); 70,36 (t, 3'-CH); 61,29 (s, 5'-CH<sub>2</sub>); 39,29 (s, 2'-CH<sub>2</sub>); 38,37 (s, CH<sub>2</sub>NH<sub>2</sub>). FAB-MS  $(m/z) = 258 (M+H)^+$ . 5-{-N-[caproyl-6-(p-bromobenzamine)] aminomethyl}-2'-O-deoxyuridine (7): The compound was synthesized as described<sup>7,8</sup>. Yield: 41%, m.p.: 200-02 °C. IR: 3420s, 2940w. 2860w. 1720m, 1660s, 1640s, 1540w, 1480w, 1400w, 1280m, 1100w, 1060w, 800w, 760w. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 11,38 (1H, s, NH); 8,51 (1H, s, 3-NH); 8,1 (1H, s, 2-NH); 7,8-7,65 (5H, m, p-BrBz + 6-CH); 6.2 (1H, t, 1'-CH); 5,26 (1H, s, 3'-OH); 4,95 (1H, s, 5'-OH); 4,25 (1H, s, 3'-CH); 3,94-3,73 (3H, m, 4'-CH + 5'-CH<sub>2</sub> ); 3,51 (2H, s. CH<sub>2</sub>NHCO); 3,29-3,2 (2H, q, CH<sub>2</sub>NHBz-p-Br); 2,18-1,99 (4H, m, 2'-CH<sub>2</sub> + NHCOCH<sub>2</sub>); 1.6-1,42 and 1,38-1,16 (6H, m, 3 CH<sub>2</sub>). <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>): 172.17 (c, NHCOCH<sub>2</sub>); 165.03 (c. 4-(°O); 162,69 (c, p-BrBz-CO); 150,14 (c, 2-CO); 137,37 (t, 6-CH); 133,67 (c, Carom-CO); 131,14 and 129.18 (2 t, C'Harom.): 124.61 (c, C'arom-Br); 110,87 (c, 5-C); 87,35 (t, 4'-C'H); 83,98 (t, 1'-C'H); 70.46 (t, 3'-CH); 61.41 (s, 5'-CH<sub>2</sub>); 39.41 (s, 2'-CH<sub>2</sub>); 39.07(2); 38.74 (3s, 2 CH<sub>2</sub>NHCO + NHCO(H<sub>2</sub>); 28.75: 26.11 and 24,84 (3 s, 3 (H<sub>2</sub>). FAB-MS m/z = 554 (M+1)<sup>+</sup>. Anal. Cald. for  $C_{23}H_{29}N_4O_7Br$ ; C. 49.93; H, 5,24; N, 10,12; Br, 14,44. Found: C: 49,34, H: 5,13, N: 9,98.

**Biological Procedures. Bacterial Strains**: *Escherichia coli* cells (DH5 $\alpha$ ) Thy mutants were obtained as described<sup>14</sup>. *In vivo* DNA Labelling: Thy<sup>-</sup> cells were grown in LB medium alone, and in LB supplemented with 200 µg/mL of <u>7</u>, or thymidine. The cultures were shaken overnight at 37 °C. Phenylmethylsulfonylfluoride was added to cell lysate for protecting the BLC peptic bond from protease attack. Nuclear DNA molecules were obtained as reported<sup>15</sup>. **ELISA**. To measure the incorporation of the modified nucleotide <u>8</u> to DNA we designed a direct competitive ELISA<sup>8</sup>. The MAb and gelatin-hapten conjugate<sup>8</sup> optimum amounts, for coating the wells, were determined. To obtain a calibration curve, the concentration of free nucleoside was varied to attain the function relating absorbance with nucleotide concentration. The absorbance obtained in the competitive ELISA of hydrolyzed labeled DNA was used to estimate in the calibration curve the incorporation of thymidine analog to DNA. The experimental details in the direct competitive ELISA were described in a previous paper<sup>8</sup>. **Statistical method to estimate the absorbances** and known free nucleoside concentrations was fitted to a sigmoidal curve according to described<sup>11</sup>. Solving this equation for the absorbances obtained in the ELISA, we estimated the thymidine analog concentration. The equation was solved using an iterative method (ref).

#### REFERENCES

<sup>1</sup> Roget, A.; Teoule, R.; Bazin, H., Nucleic Acids Research 1989, 17, 7643.

<sup>2</sup> Kessler, Ch.; Mühlegger, K.; Huber, E.; von der Eltz, H.; Rüger, R., Biol. Chem. Hoppe-Seyler 1990, 371, 953.

<sup>3</sup> Singh, D.; Kumar, V.; Ganesh, K. N., Nucleic Acids Research 1990, 18, 3339.

<sup>4</sup> Cook, A. F.; Vuocolo, E.; Brakel, Ch. L., Nucleic Acids Research 1988, 16, 4077.

#### THYMIDINE ANALOG FOR LABELING OF DNA

- 5 Gibson, K. J.; Benkovics, S. J., Nucleic Acids Research 1987, 15, 6455.
- 6 Safarti, S.R.; Pochet, S.; Guerreiro, C.; Namame, A.; Huynh-Dinh, T.; Igolen, J., *Tetrahedron* 1987, 43, 3491.
- Rodríguez-Tanty, Ch.: López-Canovas, L.: López-Braut, A.: Rivero, M.: Higginson, D.: Vélez, H.: Riverón, A.: Macías, A. Nucleosides & Nucleotides 1995, 14, 219-228.
- Rodríguez-Tanty, C.; Higginson-Clarke, D.; Hernández, M.; Pérez, R.; Vélez, H.; Riverón-Rojas, A.; Macías-Cabrera, A. Nucleosides & Nucleotides 1997, 16, 455-467
- 9.- Baerwolf, D.; Langen, P., Nucleic Acid Chemistry 1978, vol.1, L. B. Townsend and R. S. Tipson, Wiley-Interscience, New York, 359.
- 10.- Knouzi, N.; Vaultier, M.; Carrié, R., Bull. de la Société Chimique de France 1985, 5, 815.
- 11.- O'Connell, M. A.; Belanger, B. A.; Haaland, P. D., Chemometrics and Intelligent Laboratory System 1993, 20, 97.
- 12.- Michelson, A. M.; Todd A. R., J. Chem. Soc. 1955, 816.
- Kampf, A., Shipchandler, M. T., Pillar, C., Wilson, R. S., Mertes, M. P., Nucleic Acid Chemistry, 1978, vol 1, L. B. Townsend y R. S. Tipson, Wiley-Interscience, New York, 381.
- Jeffres, H. Miller. Experiments in Molecular Genetics, Experiment 31- Selection of Thy-Strains with Trimethoprim, Cold Spring Harbor Laboratory 1972, Cold Spring Harbor, New York, 218-220.
- 15.- Sambrook, J.: Fritsch E.F.; Maniatis, T. Molecular Cloning. A Laboratory Manual. Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 1989.
- 16.- Demidovich, B. P.; Maron, I.A. Computational Mathematics. Mir Publishers Moscow, 1973, 273.